Forefront: How To Motivate Drug Development For Infectious Diseases
 â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â â
Problems viewing this email?
View Message In Browser
Wednesday, May 18, 2022 | The Latest Research, Commentary, And News From
Health Affairs
Dear John,
Don't miss out on our health reform-focused newsletter written by
Katie Keith. The newsletter examines health policy developments-from
legislation to litigation-and explains what these changes mean for
patients, payers, providers, and other key health care stakeholders.
Sign up for the Health Reform newsletter today.
Advisory Committee Votes
In their paper published in this month's issue of Health Affairs, C.
Joseph Ross Daval and coauthors examine the 482 new drugs and biologics
approved by the Food and Drug Administration (FDA)
between 2010 and 2021.
In the article, the authors pay particular attention to the ten drugs
approved despite a negative advisory committee vote.
They find that the number of new approved drugs receiving advisory
committee review decreased from 59 percent in 2011 to only 6 percent in
2021.
The authors also note inconsistencies in the wording of FDA questions
posed to the advisory committees. Daval and authors propose that the FDA
provide clear and specific criteria for how it chooses to subject new
drugs to external scrutiny.
Read More
Elsewhere At Health Affairs
Today in Health Affairs Forefront, William K. Bleser and coauthors
examine how to advance equity through value-based payment models.
Beth Boyer and coauthors discuss how to overcome the weak incentives
pharmaceutical companies have
to invest in treating and preventing diseases like malaria and
tuberculosis.
The authors suggest a transferable exclusivity voucher program to
motivate drug development for infectious diseases.
Want to read more content like this? Bookmark Health Affairs Forefront
to never miss an article.
Daily Digest
Unwanted Advice? Frequency, Characteristics, And Outcomes Of Negative
Advisory Committee Votes For FDA-Approved Drugs
C. Joseph Ross Daval et al.
ACO REACH And Advancing Equity Through Value-Based Payment, Part 2
William K. Bleser et al.
How To Motivate Drug Development For Infectious Diseases
Beth Boyer et al.
Â
[link removed]
[link removed]
Â
[link removed]
Â
[link removed]
Â
[link removed]
Â
mailto:
[email protected]
About Health Affairs
Health Affairs is the leading peer-reviewed journal
at the intersection of health,
health care, and policy. Published monthly by Project HOPE, the journal
is available in print and online. Late-breaking content is also found
through healthaffairs.org , Health Affairs Today
, and Health Affairs Sunday
Update . Â
Project HOPE is a global health and
humanitarian relief organization that places power in the hands of local
health care workers to save lives across the globe. Project HOPE has
published Health Affairs since 1981.
Copyright © Project HOPE: The People-to-People Health Foundation, Inc.
Health Affairs, 1220 19th Street, NW, Suite 800, Washington, DC 20036, United States
Privacy Policy
To unsubscribe from this email, update your email preferences here
.
_________________
Sent to
[email protected]
Unsubscribe:
[link removed]
Health Affairs, 1220 19th Street, NW, Suite 800, Washington, DC 20036, United States
